SZOSTAK, Barbara et al. Overview of available treatment and new drug action points in obesity pharmacology. Will GIP, glucagon, amylin replace GLP-1?. Prospects in Pharmaceutical Sciences, [S. l.], v. 23, n. 2, p. 42–49, 2025. DOI: 10.56782/pps.361. Disponível em: https://prospects.wum.edu.pl/index.php/pps/article/view/361. Acesso em: 8 may. 2025.